IRIDEX Debt to Equity Ratio 2010-2024 | IRIX
Current and historical debt to equity ratio values for IRIDEX (IRIX) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. IRIDEX debt/equity for the three months ending September 30, 2024 was 0.55.
IRIDEX Debt/Equity Ratio Historical Data |
Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
2024-09-30 |
$0.03B |
$0.00B |
10.50 |
2024-06-30 |
$0.03B |
$0.00B |
6.36 |
2024-03-31 |
$0.03B |
$0.01B |
4.26 |
2023-12-31 |
$0.03B |
$0.01B |
2.62 |
2023-09-30 |
$0.02B |
$0.01B |
1.90 |
2023-06-30 |
$0.02B |
$0.01B |
1.75 |
2023-03-31 |
$0.03B |
$0.02B |
1.58 |
2022-12-31 |
$0.03B |
$0.02B |
1.45 |
2022-09-30 |
$0.03B |
$0.02B |
1.49 |
2022-06-30 |
$0.03B |
$0.02B |
1.35 |
2022-03-31 |
$0.03B |
$0.02B |
1.25 |
2021-12-31 |
$0.03B |
$0.02B |
1.09 |
2021-09-30 |
$0.03B |
$0.03B |
1.00 |
2021-06-30 |
$0.02B |
$0.03B |
0.88 |
2021-03-31 |
$0.02B |
$0.03B |
0.93 |
2020-12-31 |
$0.01B |
$0.02B |
0.61 |
2020-09-30 |
$0.01B |
$0.02B |
0.65 |
2020-06-30 |
$0.01B |
$0.02B |
0.56 |
2020-03-31 |
$0.01B |
$0.02B |
0.46 |
2019-12-31 |
$0.01B |
$0.02B |
0.53 |
2019-09-30 |
$0.01B |
$0.02B |
0.50 |
2019-06-30 |
$0.01B |
$0.03B |
0.50 |
2019-03-31 |
$0.01B |
$0.03B |
0.48 |
2018-12-31 |
$0.01B |
$0.03B |
0.39 |
2018-09-30 |
$0.01B |
$0.03B |
0.34 |
2018-06-30 |
$0.01B |
$0.02B |
0.44 |
2018-03-31 |
$0.01B |
$0.03B |
0.37 |
2017-12-31 |
$0.01B |
$0.03B |
0.36 |
2017-09-30 |
$0.01B |
$0.04B |
0.24 |
2017-06-30 |
$0.01B |
$0.04B |
0.22 |
2017-03-31 |
$0.01B |
$0.04B |
0.19 |
2016-12-31 |
$0.01B |
$0.04B |
0.23 |
2016-09-30 |
$0.01B |
$0.04B |
0.24 |
2016-06-30 |
$0.01B |
$0.04B |
0.27 |
2016-03-31 |
$0.01B |
$0.03B |
0.24 |
2015-12-31 |
$0.01B |
$0.03B |
0.24 |
2015-09-30 |
$0.01B |
$0.03B |
0.24 |
2015-06-30 |
$0.01B |
$0.03B |
0.24 |
2015-03-31 |
$0.01B |
$0.03B |
0.24 |
2014-12-31 |
$0.01B |
$0.03B |
0.24 |
2014-09-30 |
$0.01B |
$0.03B |
0.27 |
2014-06-30 |
$0.01B |
$0.03B |
0.25 |
2014-03-31 |
$0.01B |
$0.03B |
0.24 |
2013-12-31 |
$0.01B |
$0.03B |
0.30 |
2013-09-30 |
$0.01B |
$0.03B |
0.28 |
2013-06-30 |
$0.01B |
$0.02B |
0.30 |
2013-03-31 |
$0.01B |
$0.02B |
0.26 |
2012-12-31 |
$0.01B |
$0.02B |
0.32 |
2012-09-30 |
$0.01B |
$0.02B |
0.28 |
2012-06-30 |
$0.01B |
$0.03B |
0.26 |
2012-03-31 |
$0.01B |
$0.02B |
0.27 |
2011-12-31 |
$0.01B |
$0.02B |
0.43 |
2011-09-30 |
$0.01B |
$0.02B |
0.43 |
2011-06-30 |
$0.01B |
$0.02B |
0.41 |
2011-03-31 |
$0.01B |
$0.02B |
0.47 |
2010-12-31 |
$0.01B |
$0.02B |
0.50 |
2010-09-30 |
$0.01B |
$0.02B |
0.53 |
2010-06-30 |
$0.01B |
$0.02B |
0.53 |
2010-03-31 |
$0.01B |
$0.02B |
0.63 |
2009-12-31 |
$0.01B |
$0.02B |
0.88 |
2009-09-30 |
$0.01B |
$0.01B |
0.91 |
2009-06-30 |
$0.01B |
$0.01B |
0.98 |
2009-03-31 |
$0.02B |
$0.01B |
1.27 |
Sector |
Industry |
Market Cap |
Revenue |
Computer and Technology |
Laser Systems and Components |
$0.029B |
$0.052B |
IRIDEX Corporation is the leading worldwide provider of semiconductor-based laser systems used to treat eye diseases in ophthalmology and skin lesions in dermatology. The products are sold in the United States predominantly through a direct sales force and internationally through independent distributors. The company markets the products using three brand names: IRIS Medical to the ophthalmology market, IRIDERM to the dermatology market, and Light Solutions to the research market.
|